AI assistant
CATALYST PHARMACEUTICALS, INC. — Director's Dealing 2022
Nov 22, 2022
31542_dirs_2022-11-22_8705a9b0-c317-492a-91e7-b8b1d8c543f6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2022-11-18
Reporting Person: MCENANY PATRICK J (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-11-18 | Common stock, par value $0.001 per share | M | 350000 | $2.24 | Acquired | 4252606 | Direct |
| 2022-11-18 | Common stock, par value $0.001 per share | S | 350000 | $15.622 | Disposed | 3902606 | Direct |
| 2022-11-21 | Common stock, par value $0.001 per share | M | 150000 | $2.24 | Acquired | 4052606 | Direct |
| 2022-11-21 | Common stock, par value $0.001 per share | S | 150000 | $15.332 | Disposed | 3902606 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-11-18 | Options to purchase common stock | $2.24 | M | 350000 | Disposed | 2025-12-19 | Common Stock (350000) | Direct |
| 2022-11-21 | Options to purchase common stock | $2.24 | M | 150000 | Disposed | 2025-12-19 | Common Stock (150000) | Direct |
Footnotes
F1: Shares were sold for personal reasons. Shares were not sold as a result of any disagreement with the Company and Mr. McEnany remains a director and an officer of the Company.
F2: Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $15.50 to $16.06 per share.
F3: Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $15.19 to $15.55 per share.
F4: Options vested in three equal tranches on December 19, 2019, 2020 and 2021.